PATIENT DERIVED XENOGRAFT MODEL MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Patient Derived Xenograft Model Market, By Model Type (Cell line derived models, Patient derived organoids, Genetically engineered models and Others (Primary cell derived models, cell processed models etc.)), By Implantation Method (Subcutaneous Implantation, Orthopedic Implantation and Others), By Tumor Type (Blood Cancer Models, Solid Tumor Models, Pediatric Tumor Models, Other Rare Tumor Models, Combination PDX Models, Custom PDX Models, Others), By Application (Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model and Other Tumor Model), By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutions, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments:

In July 2022, GemPharmatech (GemPharmatech Co., Ltd.) announced that it has entered into a strategic licensing agreement with Charles River Laboratories, Inc. for the exclusive distribution of its next-generation NOD CRISPR Prkdc Il2r Gamma (NCG) mouse lines in North America. Charles River will build foundation colonies with models scheduled to be commercially available in 2023.
In April 2022, Professor Kamimura's research group at Niigata University established a novel pancreatic carcinogenesis model in wild-type rats using the pancreas-targeted selective hydrodynamic gene delivery method. Source: